SCHEMBL10143671

SCHEMBL10143671

CCCCOCC1CCC(/C(N)=N/O/C(=C/C2OC(C)O2)C(=O)OCC)(N(C)C(=O)OC(C)(C)C)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10143636 0.90
SCHEMBL10144301 0.80 SMN1; SMN2 (0.34)
SCHEMBL10120963 0.77 L3MBTL1 (0.32)
SCHEMBL10120954 0.68 ASGR1 (0.32)
SCHEMBL10143599 0.67 SMN1; SMN2 (0.36)
SCHEMBL10144487 0.66 SPHK1 (0.39)
SCHEMBL17695817 0.64 SMN1; SMN2 (0.40)
SCHEMBL13255730 0.62 SPHK1 (0.38)
SCHEMBL10121070 0.61
SCHEMBL10120768 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
WO-2010088167-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed